Sitemap
Pages
Sitemap
News
- Advancing NO Innovation: ConvaNiox Approved
- 30 Technology Enrolls First Patient in Pioneering NOPA Trial for New Inhaled Antimicrobial RESP303
- 30 Technology announces interim results from Phase 2 tuberculosis trial
- 30 Technology- EMA Approval to launch a Phase 1/2a trial in patients with Non-Cystic Fibrosis Bronchiectasis
- 30 Technology completes final patient dosing in its TB study in South Africa
- 30 Technology Holds Inaugural Scientific Advisory Board Meeting
- 30 Technology launches a critical clinical trial in patients with newly diagnosed tuberculosis
- 30 Technology expands its clinical team
- 30 Technology receives regulatory approval for TASK tuberculosis Study in South Africa
- 30 Technology Expands Its Scientific Team And Opens New Innovation Hub At Scale Space, Imperial College London
- 30 Technology enters into a strategic Licencing Agreement to develop new treatments for multi-drug resistant tuberculosis
- 30 Technology launches a critical clinical trial of RESP301 in cystic fibrosis patients with serious lung infections
- Thirty Respiratory receives approval for multicentre post-exposure clinical trial of RESP301 to prevent transmission of COVID-19 in the community
- 30 Technology announces first patients enrolled in UK clinical trial (NOCoV2) for the treatment of COVID-19
Press Releases